Biotech company Admedus has completed an oversubscribed $8 million share placement as it looks to push marketing for its CardioCel regenerative tissue product in Europe and the US.
Biotech company Admedus has completed an oversubscribed $8 million share placement as it looks to push marketing for its CardioCel regenerative tissue product in Europe and the US.